Applied Genetic Technologies (AGTC) Given a $8.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $8.00 price target on Applied Genetic Technologies (NASDAQ:AGTC) in a report published on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.

AGTC has been the subject of a number of other research reports. Zacks Investment Research lowered Applied Genetic Technologies from a hold rating to a sell rating in a research note on Tuesday, January 9th. ValuEngine lowered Applied Genetic Technologies from a sell rating to a strong sell rating in a research report on Sunday, December 31st. Wedbush reissued an outperform rating and set a $9.00 price objective on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Finally, Cantor Fitzgerald reissued a hold rating and set a $9.00 price objective on shares of Applied Genetic Technologies in a research report on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Applied Genetic Technologies has a consensus rating of Hold and an average target price of $10.17.

Shares of Applied Genetic Technologies (AGTC) opened at $3.95 on Friday. Applied Genetic Technologies has a 52 week low of $3.25 and a 52 week high of $8.40. The company has a market capitalization of $76.90, a price-to-earnings ratio of -19.75 and a beta of 2.03.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. analysts predict that Applied Genetic Technologies will post -1.14 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Nine Chapters Capital Management LLC purchased a new position in Applied Genetic Technologies during the third quarter valued at $113,000. Citadel Advisors LLC lifted its position in Applied Genetic Technologies by 304.6% during the third quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 31,070 shares during the period. Virtu KCG Holdings LLC purchased a new position in Applied Genetic Technologies during the second quarter valued at $178,000. ClariVest Asset Management LLC lifted its position in Applied Genetic Technologies by 18.5% during the third quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 15,491 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Applied Genetic Technologies by 1,080.3% during the second quarter. Goldman Sachs Group Inc. now owns 143,606 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 131,439 shares during the period. 46.59% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2018/02/10/applied-genetic-technologies-agtc-given-a-8-00-price-target-by-hc-wainwright-analysts.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply